Fig. 2: Study design.

a First hydroxyurea (HU) treatment; b Hematocrit, other laboratory assessments, and phlebotomy measured ±14 days in the 6–9 month-post-index window; c Observations included: respiratory, heart, pulse, weight, height, body mass index, systolic blood pressure, diastolic blood pressure and demographics (gender, race, ethnicity, region, division, and age at index); d Adapted for real world evidence (RWE) with no hydroxyurea dosage applied.